Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as $34.01 and last traded at $33.33, with a volume of 1041 shares traded. The stock had previously closed at $34.87.
Analyst Ratings Changes
AMPH has been the subject of a number of research reports. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 target price for the company. Piper Sandler cut Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $66.00 to $36.00 in a report on Tuesday. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $50.33.
Check Out Our Latest Research Report on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of 10.93, a price-to-earnings-growth ratio of 1.07 and a beta of 0.81. The business's 50 day moving average is $38.64 and its 200 day moving average is $43.81.
Insider Transactions at Amphastar Pharmaceuticals
In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 6,893 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total value of $336,929.84. Following the completion of the sale, the executive vice president now owns 118,388 shares in the company, valued at $5,786,805.44. This represents a 5.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the transaction, the director now owns 31,471 shares in the company, valued at approximately $1,535,784.80. This represents a 13.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,893 shares of company stock valued at $1,329,570 over the last quarter. Company insiders own 27.10% of the company's stock.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after buying an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp raised its position in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock worth $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock worth $44,674,000 after buying an additional 14,015 shares during the period. Portolan Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 201.1% in the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company's stock worth $15,906,000 after purchasing an additional 218,901 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Amphastar Pharmaceuticals by 4.8% during the fourth quarter. Nordea Investment Management AB now owns 279,714 shares of the company's stock worth $10,386,000 after buying an additional 12,851 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
